Octreotride

# Octreotride ## Overview - **Classification**: Somatostatin Analog - **Mechanism**: Mimics natural somatostatin; inhibits release of growth hormone, TSH, glucagon, insulin, and various GI regulating peptides. ## Primary Indications 1. **Acromegaly**: Reduction of GH and IGF-1 levels. 2. **Carcinoid Tumors**: Control of symptoms (diarrhea, flushing). 3. **VIPomas**: Management of severe watery diarrhea. 4. **Esophageal Variceal Bleeding**: Acute control of bleeding (off-label/hospital use). ## Adult Dosing ### Standard Dosing (Subcutaneous/Intravenous) **Carcinoid/VIPoma Symptoms** - **Dose**: **100 mcg to 600 mcg** (daily dose) in 2-4 divided doses. - **Frequency**: Every 8 hours (TID) to every 12 hours (BID). - **Route**: Subcutaneous (SC). - **Initial Dose**: **50 mcg SC** TID, titrated based on response/tolerance. **Acromegaly (Initial SC Treatment)** - **Dose**: **50 mcg** SC. - **Frequency**: Three times daily (TID). - **Max Dose (SC)**: Usually **500 mcg** TID, but rarely needed. **Acute Variceal Bleeding (IV)** - **Dose (Loading)**: **50 mcg** bolus. - **Dose (Infusion)**: **25 mcg to 50 mcg per hour** continuous infusion. - **Route**: Intravenous (IV). - **Duration**: Up to 5 days. ### Dose Adjustments - **Renal Impairment**: No specific dose adjustment needed for SC route. Monitor closely. - **Hepatic Impairment**: Dose reduction may be necessary, especially in severe cirrhosis. Start at **50% lower initial dose**. - **Elderly Patients**: Start at the lower end of the dosing range due to potential hepatic decline. ## Pediatric Dosing *\*Octreotide use in pediatrics is primarily limited to treating functional tumors (e.g., GH hypersecretion, tumors causing refractory diarrhea) and is generally **off-label** but accepted in specialized centers.* ### Neonates (0-28 days) - **Indications**: Refractory congenital hyperinsulinism (rare use). - **Dose**: **1 to 10 mcg/kg/day** continuous infusion or divided doses. - **Frequency**: Every 6 to 8 hours (Q6-8H). - **Special Notes**: High risk of **necrotizing enterocolitis (NEC)**; use with extreme caution. Closely monitor glucose. ### Infants (1-12 months) - **Dose**: **1 to 10 mcg/kg/dose**. - **Frequency**: Every 8 hours (TID). - **Maximum**: **10 mcg/kg/dose**. ### Children (1-12 years) - **Dose**: **5 to 10 mcg/kg/day** divided into 2-4 doses. - **Frequency**: Every 6 to 12 hours. - **Maximum**: Usually not to exceed **50 mcg to 100 mcg per dose** (similar to adult starting dose per injection). ### Adolescents (13-18 years) - **Dose**: Titrate towards adult dosing strategies and total daily limits. Initiate at **50 mcg** TID SC. - **Maximum**: Adult dose limit based on indication. ## Safety Information ### Contraindications - **Absolute**: Hypersensitivity to octreotide or somatostatin analogs. ### Common Adverse Effects - **Very Common (>10%)**: Diarrhea, abdominal pain, nausea, cholelithiasis (gallstones). - **Common (1-10%)**: Injection site pain, headache, constipation, hypothyroidism, hyperglycemia. - **Serious but Rare**: Pancreatitis, cardiac conduction abnormalities (bradycardia), B12 deficiency. ### Key Drug Interactions - **Cyclosporine**: Octreotide decreases cyclosporine absorption; **monitor trough levels** closely. - **Insulin/Oral Hypoglycemics**: Octreotide affects glucagon/insulin balance; **monitor blood glucose** and adjust antidiabetic dose. - **Bradycardia-inducing Drugs (e.g., Beta-blockers)**: Increased risk of severe bradycardia; **monitor vital signs and ECG**. ## Monitoring & Follow-up - **Before Treatment**: Baseline ECG, gallbladder ultrasound (if long-term therapy planned), baseline TSH/T4, B12 levels. - **During Treatment**: Serum glucose (monitor for hypo/hyperglycemia) (weekly initially, then monthly). - **During Treatment**: Thyroid function (TSH/T4) (every 6-12 months). - **During Treatment (Acromegaly)**: GH and IGF-1 levels (every 4 weeks until stable). - **Clinical Signs**: Monitor for signs of cholecystitis (RUQ pain) and cardiac rhythm changes. ## Clinical Pearls - 💡 **Tip 1**: Octreotide SC injection technique is crucial; allow solution to reach room temperature before injection to minimize pain. - 💡 **Tip 2**: Gallstone prophylaxis (e.g., ursodeoxycholic acid) may be required for long-term use, especially in high-dose settings. - 💡 **Tip 3**: Due to interference with nutritional absorption, long-term patients may require B12 supplementation. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.